Accessibility/Mobile Features
Skip Navigation
Skip to Content
Editorial News
Business
Classified Sites

The Canadian Press - ONLINE EDITION

FDA accepts first application for approval of a biosimilar drug, could decide in 10 months

WASHINGTON - The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug.

Nearly five years after Congress passed a law enabling future approval of biosimilars, for the first time the FDA has accepted an application to sell a similar, but not identical, version of a biologic drug.

The FDA is evaluating Swiss drugmaker Novartis AG's application to sell a biosimilar version of Neupogen, which brought maker Amgen Inc. $1.4 billion in sales last year. Neupogen, known chemically as filgrastim, treats a dangerous decrease in infection-fighting white blood cells, common in cancer patients getting certain treatments.

Sandoz, the generic division of Novartis, already sells three biosimilar drugs, including filgrastim, in about 60 other countries.

The FDA should make its decision after a standard 10-month review, a spokeswoman said.

"Biosimilars have been successfully used in Europe and other markets for years," Ralph Neas, CEO of the Generic Pharmaceutical Association, said in a statement. "Filgrastim's filing acceptance moves us closer to the day when U.S. patients that currently must rely on costly brand biologics for treatment will have more choices."

Biologic drugs are powerful, injected medicines produced in living cells. They are much more expensive to produce than traditional pills made by mixing chemicals. Some newer ones cost more than $100,000 per treatment course, making copayments unaffordable for many patients.

That also adds up to billions in annual costs for insurance companies and government health programs, which are trying to rein in spending. Thus the Affordable Care Act, which President Obama signed into law early in 2010, includes the Biologics Price Competition and Innovation Act's requirements for approval of cheaper biosimilars.

When a traditional drug loses patent protection, multiple companies start selling copycat pills at up to 90 per cent less than the brand-name medicine. That's why nearly 85 per cent of prescriptions dispensed in the U.S. are generic pills.

To gain approval, generic drugmakers need only prove to the FDA that their pills are chemically identical to the original drug.

Companies wanting FDA approval to make biosimilars must prove their product is "highly similar" to the original medicine — and also conduct expensive studies, first in animals and then in patients, to prove its safety, purity and potency. They'll still be costly to manufacture, so biosimilar drugs likely will only cost about a third less than the original biologic medicine.

Still, Express Scripts, the country's largest prescription benefit manager, last year estimated the U.S. could save $250 billion between 2014 and 2024, if biosimilar versions of filgrastim and 10 other likely drug candidates hit the market.

  • Rate this Rate This Star Icon
  • This article has not yet been rated.
  • We want you to tell us what you think of our articles. If the story moves you, compels you to act or tells you something you didn’t know, mark it high. If you thought it was well written, do the same. If it doesn’t meet your standards, mark it accordingly.

    You can also register and/or login to the site and join the conversation by leaving a comment.

    Rate it yourself by rolling over the stars and clicking when you reach your desired rating. We want you to tell us what you think of our articles. If the story moves you, compels you to act or tells you something you didn’t know, mark it high.

Sort by: Newest to Oldest | Oldest to Newest | Most Popular 0 Commentscomment icon

You can comment on most stories on brandonsun.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.

There are no comments at the moment. Be the first to post a comment below.

Post Your Commentcomment icon

Comment
  • You have characters left

The Brandon Sun does not necessarily endorse any of the views posted. Comments are moderated before publication. By submitting your comment, you agree to our Terms and Conditions. New to commenting? Check out our Frequently Asked Questions.

letters

Make text: Larger | Smaller

Brandon Sun Business Directory
The First World War at 100

Social Media

Canadian Mortgage Rates